Business
Currency:USD
2025/Q1
Stock NameRevenueRatio
Developing and commercializing innovative therapies for retinal diseases and other eye conditions10.7M100.00%
Region
Currency:USD
2024/FY
Stock NameRevenueRatio
United States63.72M100.00%